ACADIA Pharmaceuticals Inc. (ACAD) 20 Days SMA touch 9.33%: Odds are Looking very much in favour

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) open the trading on May 25, 2023, with a bit cautious approach as it glided -4.68% to $24.45. During the day, the stock rose to $26.04 and sunk to $24.045 before settling in for the price of $25.65 at the close. Taking a more long-term approach, ACAD posted a 52-week range of $12.24-$25.73.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 32.90%. Meanwhile, its Annual Earning per share during the time was 5.80%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -27.70%. This publicly-traded company’s shares outstanding now amounts to $162.26 million, simultaneously with a float of $161.70 million. The organization now has a market capitalization sitting at $3.79 billion. At the time of writing, stock’s 50-day Moving Average stood at $20.49, while the 200-day Moving Average is $17.94.

While finding the extent of efficiency of the company that is accounted for 540 employees. It has generated 1,008,255 per worker during the last fiscal year. Meanwhile, its income per employee was -421,004. The stock had 8.06 Receivables turnover and 0.80 Total Asset turnover. For the Profitability, stocks gross margin was +98.03, operating margin was -43.23 and Pretax Margin of -41.27.

ACADIA Pharmaceuticals Inc. (ACAD) Ownership Facts and Figures

Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. ACADIA Pharmaceuticals Inc.’s current insider ownership accounts for 0.10%, in contrast to 94.90% institutional ownership. According to the most recent insider trade that took place on May 24, this organization’s Director bought 553,263 shares at the rate of 25.48, making the entire transaction reach 14,096,825 in total value, affecting insider ownership by 39,317,673. Preceding that transaction, on May 23, Company’s Director bought 209,053 for 25.41, making the whole transaction’s value amount to 5,312,458. This particular insider is now the holder of 38,811,515 in total.

ACADIA Pharmaceuticals Inc. (ACAD) Earnings and Revenue Records

So, what does the last quarter earnings report of the company that was made public on 3/30/2023 suggests? It has posted -$0.27 earnings per share (EPS) not meeting the forecaster’s viewpoint (set at -$0.21) by -$0.06. This company achieved a net margin of -41.76 while generating a return on equity of -45.89. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.08 per share during the current fiscal year.

ACADIA Pharmaceuticals Inc.’s EPS decrease for this current 12-month fiscal period is -27.70% and is forecasted to reach -0.02 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 25.00% through the next 5 years, which can be compared against the 5.80% growth it accomplished over the previous five years trading on the market.

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) Trading Performance Indicators

Let’s observe the current performance indicators for ACADIA Pharmaceuticals Inc. (ACAD). It’s Quick Ratio in the last reported quarter now stands at 2.20. The Stock has managed to achieve an average true range (ATR) of 0.85. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 7.29.

In the same vein, ACAD’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.90, a figure that is expected to reach -0.19 in the next quarter, and analysts are predicting that it will be -0.02 at the market close of one year from today.

Technical Analysis of ACADIA Pharmaceuticals Inc. (ACAD)

[ACADIA Pharmaceuticals Inc., ACAD] recent stats showed that its last 5-days Average volume was superior the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 86.44% While, its Average True Range was 0.92.

Raw Stochastic average of ACADIA Pharmaceuticals Inc. (ACAD) in the period of the previous 100 days is set at 84.52%, which indicates a major rise in contrast to 71.71% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 38.60% that was lower than 39.42% volatility it exhibited in the past 100-days period.